Royalty Pharma(RPRX) - 2024 Q1 - Quarterly Results

Exhibit 99.1 ROYALTY PHARMA REPORTS FIRST QUARTER 2024 RESULTS • Royalty Receipts growth of 14% driving Portfolio Receipts of $717 million • Net cash provided by operating activities of $665 million • Full year 2024 guidance confirmed: Portfolio Receipts expected to be $2,600 to $2,700 million • Commitment to grow dividend by mid-single digit percentage annually NEW YORK, NY, May 9, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2024 and confirmed full yea ...